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CASE REPORT
A case of chest tightness variant asthma : the usefulness of  
fractional exhaled nitric oxide as a marker for the diagnosis 
and clinical improvement.
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Abstract : A 50-year-old woman was referred to our hospital for further examination of severe constricting pain 
at the right-side dominant anterior chest. She had medical history of outgrown childhood asthma and allergies 
to several animals. Chest auscultation revealed no wheezes, rhonchi and other crackles. Laboratory findings 
showed an eosinophilia and an elevation of total immunoglobulin E. The results of an electrocardiogram, a chest 
X-ray and a chest CT were unremarkable. A fractional exhaled nitric oxide value remarkably elevated, but the 
abnormalities in pulmonary function test were modest. Her chest pain was ameliorated after inhaling procaterol. 
Based on these findings, a diagnosis of chest tightness variant asthma was formulated, and we started treatment 
with inhaled corticosteroid / long acting β2 agonist. At two-weeks after treatment, her symptom markedly im-
proved and a fractional exhaled nitric oxide value decreased, which led to a definitive diagnosis of chest tight-
ness variant asthma. A fractional exhaled nitric oxide value further decreased to the normal range in consistent 
with symptom disappearance at 10-months after treatment, indicating the usefulness of fractional exhaled nitric 
oxide as a promising marker for the diagnosis and clinical improvement of chest tightness variant asthma. J. 
Med. Invest. 68 : 389-392, August, 2021
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INTRODUCTION
 
Asthma is a chronic inflammatory respiratory disease that 
is commonly characterized by airway hyperresponsiveness and 
reversible airway obstruction in the airway, and all asthmat-
ics share common physiologic airway abnormalities in theory. 
Despite these shared features, asthma has been recognized to 
have the great heterogeneity and may be manifested in various 
clinical phenotypes (1, 2). In 2013, Shen et al. reported patients 
with atypical asthma whose sole presenting clinical manifesta-
tion was chest tightness and referred to this type of asthma as 
chest tightness variant asthma (CTVA) (3). CTVA is considered 
as a rare variant form of asthma, but sufficient data are yet to 
be collected to clarify its accurate disease concept. In the present 
report, we demonstrated a case of CTVA who presented chest 
pain as the sole symptom and highlighted the usefulness of frac-
tional exhaled nitric oxide (FeNO) as a promising marker for the 
diagnosis and clinical improvement of CTVA. 
CASE REPORT
A 50-year-old woman was referred to our hospital from a 
nearby clinic for further examination of severe constricting pain 
at the right-side dominant anterior chest from three weeks ago. 
It was the episode that she had never experienced before, and 
the episodes of severe constricting pain lasted for a few minutes, 
which followed by the weak pain of several-hour duration. While 
she did not have any other complaints, her symptom did not ame-
liorate by non-steroidal anti-inflammatory drugs. She required 
maintenance dialysis due to chronic kidney disease from 12 
years ago and had medical history of outgrown childhood asth-
ma and allergies to several animals. She was a never smoker, 
and no significant social or family history was reported.
The physical examinations at the initial admission revealed 
body temperature of 36.6℃, blood pressure of 144 / 91 mmHg, 
pulse of 80 beats per minute and percutaneous oxygen satu-
ration of 98% on room air. The cardiovascular examination 
was unremarkable. There were no wheezes, rhonchi and other 
crackles in chest auscultation. No evident pretibial and foot pad 
edema were seen. The remainder of the physical examinations 
was normal. Hematological findings showed normal white blood 
cell count (7400 / μL) with eosinophilia (1088 / μL), and mild ane-
mia. Laboratory findings showed elevated levels of blood urea 
nitrogen (45.1 mg / dL), creatinine (8.16 mg / dL), potassium (5.5 
mEq / L), and N-terminal pro-brain natriuretic peptide (1560 
pg / mL) due to chronic renal failure. Serum levels of creatine ki-
nase, creatine kinase-MB, and C-reactive protein were normal. 
An elevated level of serum total immunoglobulin E (IgE) was ob-
served (779.0 U / mL). Serum antigen-specific IgEs were not mea-
sured. The remainder of laboratory test results is shown in Table 
1. The results of an electrocardiogram, a chest X-ray and a chest 
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CT were unremarkable. A value of FeNO remarkably elevated at 
106 parts per billion (ppb). In a pulmonary function test, values 
of percent predicted peak expiratory flow (%PEF), percent pre-
dicted V50 (%V50), and percent predicted V25 (%V25) slightly 
decreased, while those of forced expiratory volume in 1 second 
(FEV1), forced vital capacity (FVC), FEV1 / FVC, and percent 
predicted vital capacity (%VC) were normal. Airway reversibility 
test was not performed following the patient’s wishes. Her chest 
pain was ameliorated after inhaling procaterol.
Based on these findings, a diagnosis of CTVA was formulated, 
and we started treatment with inhaled corticosteroid (ICS) / long 
acting β2 agonist (LABA) at the initial visit. At two-weeks 
after the treatment initiation, her symptom markedly improved 
and a FeNO value decreased at 25 ppb. By the confirmation of 
remarkable clinical improvement in response to ICS / LABA, a 
definitive diagnosis of CTVA was made. She continues treatment 
with ICS / LABA even now and chest pain has completely dis-
appeared. At 10-months after the treatment initiation, a FeNO 
value further decreased at 7 ppb (Fig. 1). 
DISCUSSION
Asthma is a chronic inflammatory respiratory disease that is 
commonly characterized by inflammation, hyperresponsiveness, 
and reversible obstruction in the airway. By definition, all asth-
matics share common physiologic airway abnormalities. Despite 
these shared features, the great heterogeneity in the severity 
of airflow limitation and symptoms has been recognized (1). 
Although the typical symptoms of recurrent episodes of wheezes, 
dyspnea, chest tightness, and cough, occur simultaneously (4), 
asthma may be manifested in various clinical phenotypes (2). 
An atypical patient with asthma who presented solely with chest 
tightness was firstly reported by Farr et al. (5), and this pheno-
type was called as chest pain variant asthma (6, 7). However, 
this is not generally appreciated, perhaps because these works 
were published 30-40 years ago. In 2013, Shen et al. reported 24 
patients with asthma whose sole presenting clinical manifesta-
tion was chest tightness and referred to this type of asthma as 
CTVA (3). As is the case in patients with classic asthma or cough 
variant asthma (CVA) (8, 9), patients with CTVA also presented 
Table 1.　Laboratory data at the first admission
Hematology Biochemistry Pulmonary function test
WBC 7,400 /μL AST 9 IU/L VC 2.71 L
  Neu   48.8 % ALT 9 IU/L %VC 100.7 %
  Lymph 28.4 % ALP 81 U/L FVC 2.76 L
  Mono 7.7 % LDH 134 IU/L %FVC 107.8 %
  Eos 14.7 % γ-GTP 15 U/L FEV1 2.14 L
  Baso 0.4 % CK 261 U/L FEV1/FVC 77.54 %
RBC 337×104 /μL CK-MB 9 IU/L %FEV1 98.6 %
Hb 10.9 g/dL T-bil 0.4 mg/dL PEF 5.61 L
Ht  33.2 % TP 7.5 g/dL %PEF 75.0 %
Plt 21.1×104 /μL Alb 3.9 g/dL V50 2.34 L
T-cho 153 mg/dL %V50 70.1 %
Amy 137 IU/L V25 0.57 L
BUN 45.1 mg/dL %V25 42.2 %







IgE, immunoglobulin E ; NT-proBNP, N-terminal pro-brain natriuretic peptide ; VC, vital capacity ; %VC, percent predicted vital capac-
ity ; FVC, forced vital capacity ; %FVC, percent predicted forced vital capacity ; FEV1, forced expiratory volume in 1 second ; %FEV1, 
percent predicted forced expiratory volume in 1 second ; PEF, peak expiratory flow ; %PEF, percent predicted peak expiratory 
flow ; %V50, percent predicted V50 ; %V25, percent predicted V25 ; FeNO, fractional exhaled nitric oxide ; ppb, parts per billion
Figure 1.　Comparison of FeNO values before and after treatment 
for CTVA.
FeNO values remarkably decreased at two weeks and 10 months after 
the treatment initiation compared with that at the initial admission. 
FeNO values were measured by NIOX VERO® electrochemical analyzer 
(Aerocrine AB, Solna, Sweden) at a flow rate of 50 mL / seconds and 
were expressed as ppb.
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with eosinophilic airway inflammation. Recently, Yan et al. ad-
vocated the definition of CTVA. According to their criteria, the 
diagnosis of CTVA is made based on the chest pain or tightness 
being the sole symptom and at least one of the following condi-
tions was met : 1) an increase of > 12% and > 200 mL in FEV1 
after inhaling short acting β2 agonist ; 2) airway hyperrespon-
siveness as evidenced by a positive finding of bronchial provo-
cation test ; 3) a weekly variability in diurnal PEF of greater 
than 10% ; and 4) a marked clinical improvement in response 
to β2 agonists, with or without ICS (10). The present case also 
revealed chest pain as the sole symptom and had medical history 
of outgrown childhood asthma and allergies to several animals 
with peripheral blood eosinophilia. Her chest pain was amelio-
rated after inhaling procaterol and had completely disappeared 
in response to the treatment with ICS / LABA. Taken together 
these findings, we made a definitive diagnosis of CTVA.
The clinical phenotypes of asthma are known to be remarkably 
different among patients, and it is not unusual in asthmatics for 
one or more of main symptoms to be absent. Thus, asthma with 
atypical clinical features such as chest pain and tightness, may 
be misdiagnosed as conditions such as chronic bronchitis, car-
diovascular diseases and mental disorders (11). Edmondstone 
investigated the frequency and characteristics of chest pain in 
patients admitted with acute exacerbation of asthma and found 
that chest pain occurred in 76%. These observations suggested 
that chest pain is a common symptom in acute severe asthma 
(12). As the significance of asthmatic chest pain has a tendency 
to be neglected in adults, it is worthwhile reminding physicians 
that chest pain and tightness may be related to asthma rather 
than cardiovascular diseases. CTVA is considered as a rare 
disease, and there are few case reports in Japan (Table 2) (13-17). 
But the morbidity of CTVA has possibility to be underestimated 
for abovementioned reasons. For the adequate treatment and 
symptom relief of CTVA patients, the accurate diagnosis of the 
etiology of chest pain and tightness is an important clinical 
concern.
FeNO could be an airway eosinophilic biomarker for the as-
sessment and management of asthma (18, 19). We also demon-
strated that FeNO levels were higher in CVA and classic asthma 
than those in healthy controls and that FeNO were identified 
as an independent factor to discriminate CVA and non-CVA 
(20). Recently, Yan et al. evaluated the therapeutic response to 
standard asthma treatments among 76 patients with CTVA in 
a 52-week multicenter, prospective study (10). There were no 
significant improvements in FeNO after 52 weeks compared 
with the baseline level, while chest tightness was significantly 
ameliorated among most patients with CTVA after treatment. 
However, subgroup analysis revealed that FeNO at the first 
administration in the responsive group was markedly higher 
than that in the non-responsive group, indicating that the dis-
ease severity of CTVA was associated with FeNO values. In the 
present case, a FeNO value remarkably elevated at the initial 
visit (106 ppb), contrary to modest abnormalities in pulmonary 
function test. At 10-months after treatment with ICS / LABA, a 
FeNO value drastically decreased to the normal range (7 ppb) 
in consistent with symptom disappearance. To the best of our 
knowledge, this is the first report that FeNO might be one of 
promising candidates as a marker for the diagnosis and clinical 
improvement of CTVA.
In acute exacerbation of asthma, the mechanisms of chest pain 
are estimated as follows : The chest hyperinflates during severe 
asthma and ventilation occurs at lung volumes approaching 
total lung capacity. This increases the work of breathing as the 
respiratory muscles are required to operate at a mechanical dis-
advantage, resulting in muscle fatigue and consequent pain (12). 
Farr et al. attributed the causation of chest tightness in CTVA 
patients to the remarkable air trapping and enlarged lungs 
by the severely and marginally obstruction of large and small 
airways, respectively (5). However, the pathogenesis of chest 
pain and tightness in CTVA patients remains unclear. Since 
sufficient data are yet to be collected to clarify whether CTVA 
can be defined as an independent clinical phenotype regarding 
the prevalence, risk factors, course of disease, clinical features, 
management, and prognosis, further studies are warranted to 
establish the accurate disease concept of CTVA.
In conclusion, we herein reported a case of CTVA who had 
chest pain as the sole symptom. A remarkable improvement of 
symptom in response to the treatment with ICS / LABA led to 
a definitive diagnosis of CTVA. While a FeNO value remark-
ably elevated at the initial visit, it drastically decreased after 
treatment in consistent with the symptom relief, suggesting 
that FeNO might be a promising marker for the diagnosis and 
clinical improvement of CTVA.
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Table 2.　Case reports of chest tightness variant asthma in Japan.
Ref. No. First author Age Gender Diagnosis Symptom Wheezes History of asthma
Inhalation of 
bronchodilator
13 Kashiwagi H 51 M Effect of asthma drugs, diagnosis of asthma
Chest pain, 
cough, dyspnea － ＋ Effective
14 Sano Y 37 M Effect of asthma drugs, methacholine test positive Chest pain － ＋ Effective
15 Suko M 24 M Effect of bronchodilator,acetylcholine test positive
Chest pain, cough, 
dyspnea, headache － － Effective
16 Taniguchi H 45 F Effect of LTRA Chest pain － ＋ －
17 Taniguchi H 37 M Effect of bronchodilator Chest pain, headache － － Effective
Present Case Hanibuchi M 50 F Effect of ICS / LABA, elevation of FeNO value Chest pain － ＋ Effective
LTRA, leukotriene receptor antagonist ; ICS / LABA, inhaled corticosteroid / long acting β2 agonist ; FeNO, fractional exhaled nitric oxide
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